ストックスクリーナーアプリを入手
7.18
3.88%
-0.29
アフターアワーズ：
7.19
0.01
+0.14%
前日終値:
$7.47
開ける：
$7.53
24時間の取引高:
3.19M
Relative Volume:
0.77
時価総額：
$1.38B
収益：
$71.80M
当期純損益:
$-183.59M
株価収益率:
-6.8102
EPS:
-1.0543
ネットキャッシュフロー:
$-186.52M
1週間 パフォーマンス:
-4.52%
1か月 パフォーマンス:
-1.37%
6か月 パフォーマンス:
-10.70%
1年 パフォーマンス:
-7.12%
1日の値動き範囲:
$7.025
$7.615
1週間の範囲:
$6.92
$7.615
52週間の値動き範囲:
$5.02
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
7.18 | 1.44B | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-05 | 開始されました | BofA Securities | Buy |
| 2025-12-12 | 繰り返されました | Wedbush | Outperform |
| 2025-12-09 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-08-04 | 開始されました | Canaccord Genuity | Buy |
| 2025-07-28 | 開始されました | Oppenheimer | Outperform |
| 2025-07-16 | 開始されました | Citigroup | Buy |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 開始されました | Wedbush | Outperform |
| 2025-02-25 | 開始されました | Jefferies | Buy |
| 2024-10-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | 再開されました | JP Morgan | Overweight |
| 2024-09-19 | 開始されました | B. Riley Securities | Buy |
| 2024-09-09 | 開始されました | JP Morgan | Overweight |
| 2024-05-15 | 開始されました | Wells Fargo | Overweight |
| 2023-12-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 開始されました | Raymond James | Outperform |
| 2023-05-24 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-07-15 | 開始されました | Cowen | Market Perform |
| 2019-04-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-08-07 | 開始されました | Stifel | Buy |
| 2018-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-19 | 繰り返されました | Mizuho | Buy |
| 2017-02-15 | 開始されました | H.C. Wainwright | Buy |
| 2016-11-10 | 再開されました | Leerink Partners | Outperform |
| 2015-12-07 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-12-07 | 開始されました | Jefferies | Buy |
| 2015-12-07 | 開始されました | Leerink Partners | Outperform |
| 2015-12-07 | 開始されました | Sun Trust Rbsn Humphrey | Buy |
すべてを表示
Wave Life Sciences Ltd (WVE) 最新ニュース
Wave Life Sciences to present WVE-006 trial data at ATS - Investing.com
Pictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVE - MarketBeat
A Look At Wave Life Sciences (WVE) Valuation After Q1 2026 Results And RNA Pipeline Progress - simplywall.st
WAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street Zen - MarketBeat
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Wave Life Sciences (NASDAQ: WVE) proposes one‑for‑one redomiciliation to Delaware - Stock Titan
Wave Life Sciences 2025 Executive Compensation, Governance, and Business Highlights – 10-K/A Report - Minichart
MSN Money - MSN
Canaccord lowers Wave Life Sciences stock price target on valuation By Investing.com - Investing.com India
WVE Maintained by Canaccord Genuity -- Price Target Lowered to $43.00 - GuruFocus
Wave Life Sciences Signals Momentum In Earnings Call - The Globe and Mail
Wave Life Sciences : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Wave Life Sciences (Nasdaq: WVE) details 2025 milestones, cash and executive pay - Stock Titan
Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2026 Earnings Call Transcript - Insider Monkey
B. Riley Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $31 - Moomoo
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $43 - Moomoo
WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan
Does Strong Q1 2026 Beat and Narrower Loss Reshape The Bull Case For Wave Life Sciences (WVE)? - simplywall.st
Duchenne Muscular Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Vertex Pharma, Bioleaders Corp., Wave Life Sciences, REGENXBIO - Barchart.com
RBC Capital Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $15 - Moomoo
WAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6%Here's What Happened - MarketBeat
B. Riley Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
WAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
WVE Maintained by Truist Securities -- Price Target Lowered to $15 - GuruFocus
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $15 to $36 - Moomoo
Truist Financial Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $15 - Moomoo
Wave Life Sciences Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Wave Life Sciences: Q1 Earnings Snapshot - theheraldreview.com
Truist assumes coverage on Wave Life Sciences stock with buy rating - Investing.com India
WAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Advancements - GuruFocus
WAVE Life Sciences Q1 2026 Earnings Call Transcript - MarketBeat
Wave Life Sciences (WVE) Q1 Revenue Surge Tests Bearish Profitability Concerns - simplywall.st
Clear Street Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
RBC Capital reiterates Wave Life Sciences stock rating on obesity pipeline progress By Investing.com - Investing.com South Africa
RBC Capital reiterates Wave Life Sciences stock rating on obesity pipeline progress - Investing.com Canada
WAVE Life Sciences Q1 Earnings Call Highlights - MarketBeat
Wave (WVE) Q1 2025 Earnings Call Transcript - The Motley Fool
WAVE Life Sciences (NASDAQ:WVE) Trading 5.5% HigherTime to Buy? - MarketBeat
BofA cuts Wave Life Sciences stock price target on trial focus - Investing.com
Is WAVE Life Sciences (WVE) Overvalued After Q1 2026 8-K? GF Sco - GuruFocus
BofA cuts Wave Life Sciences stock price target on trial focus By Investing.com - Investing.com India
Clear Street cuts Wave Life Sciences stock price target on obesity trial outlook - Investing.com Canada
Earnings call transcript: Wave Life Sciences Q1 2026 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Wave Life Sciences Q1 2026 beats EPS forecast - Investing.com
Wave Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Wave Life Sciences (WVE) Reports Strong Q1 Revenue and Advances WVE-007 Development - GuruFocus
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Wave Life Sciences 1Q Research and Development Expenses $47.4M >WVE - Moomoo
Q1 2026 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Wave Life Sciences (NASDAQ:WVE) Beats Q1 Estimates as Obesity Program Accelerates - ChartMill
Wave Life Sciences Ltd (WVE) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):